Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer

Guo,Liying; Zhu,Qianwen; Aisimutuola,Mulati; Yilamu,Dilimina; Liu,Sha; Jakulin,Adina

doi:10.3892/etm.2015.2380

Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer

Authors:
- Liying Guo
- Qianwen Zhu
- Mulati Aisimutuola
- Dilimina Yilamu
- Sha Liu
- Adina Jakulin
View Affiliations

Affiliations: Department of Breast Cancer, Digestive and Vascular Center, First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China, Department of General Surgery, Affiliated Hospital of Taishan Medical University, Tai'an, Shandong 271000, P.R. China
Published online on: March 23, 2015 https://doi.org/10.3892/etm.2015.2380
Pages: 2147-2150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression of estrogen receptor β (ERβ) in triple‑negative and triple‑positive breast cancer patients, and evaluate its utility as a prognostic factor. Between January 2000 and December 2010, primary tumor tissue samples were collected from 234 subjects, including 107 triple‑negative and 127 triple‑positive breast cancer patients. The samples were embedded in paraffin and immunohistochemical staining was conducted to determine the expression levels of ERβ. The Kaplan‑Meier method was used to analyze patient survival rates. ERβ expression was observed in 38/107 patients (35.5%) with triple‑negative breast cancer and 63/127 patients (49.6%) with triple‑positive breast cancer. The ERβ expression rate was significantly decreased in the patients with triple‑negative breast cancer, as compared with those with triple‑positive breast cancer (P=0.03). Analysis of the survival rates indicated that patients with triple‑negative breast cancer and positive ERβ expression exhibited poor disease progression‑free survival (DFS) compared with those with negative ERβ expression (P=0.021). However, no statistically significant difference was observed in the DFS between the triple‑positive breast cancer patients with positive and negative ERβ expression. Therefore, the expression of ERβ varies between triple‑negative and triple‑positive breast cancer patients. In addition, positive expression of ERβ indicates a poor prognosis in triple‑negative breast cancer patients; however, this is not the case for triple‑positive breast cancer patients.

View Figures

View References

1	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
2	Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK and Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 97:1254–1261. 2005. View Article : Google Scholar : PubMed/NCBI
3	Shi X, Lin XY, Huang Y, Zhang ZF, Wang RX and Zeng WC: Expressions of ER, PR, Her-2 in breast cancer. Zhong Liu Yan Jiu Yu Lin Chuang. 21:461–462,465. 2009.[(In Chinese)].
4	Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930. 1996. View Article : Google Scholar : PubMed/NCBI
5	Chang HG, Kim SJ, Chung KW, Noh DY, Kwon Y, Lee ES and Kang HS: Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene. J Mol Med (Berl). 83:132–139. 2005. View Article : Google Scholar : PubMed/NCBI
6	Cappelletti V, Celio L, Bajetta E, Allevi A, Longarini R, Miodini P, Villa R, et al: Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer. 11:761–770. 2004. View Article : Google Scholar : PubMed/NCBI
7	Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA and Rochefort H: Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res. 11:3170–3174. 2005. View Article : Google Scholar : PubMed/NCBI
8	Thomas C and Gustafsson JÅ: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 11:597–608. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006. View Article : Google Scholar : PubMed/NCBI
10	Dotzlaw H, Leygue E, Watson PH and Murphy LC: Expression of estrogen receptor-β in human breast tumors. J Clin Endocrinol Metab. 82:2371–2374. 1997. View Article : Google Scholar : PubMed/NCBI
11	Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, et al: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 9:862009. View Article : Google Scholar : PubMed/NCBI
12	Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P and Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 115:423–428. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sengupta S, Sharma CG and Jordan VC: Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig. 2:235–243. 2010.PubMed/NCBI
14	Speirs V, Adams IP, Walton DS and Atkin SL: Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J Clin Endocrinol Metab. 85:1601–1605. 2000. View Article : Google Scholar : PubMed/NCBI
15	Reis-Filho JS and Tutt AN: Triple negative tumours: A critical review. Histopathology. 52:108–118. 2008. View Article : Google Scholar : PubMed/NCBI
16	Vinayagam R, Sibson DR, Holcombe C, Aachi V and Davies MP: Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer - a retrospective study. BMC Cancer. 7:1312007. View Article : Google Scholar : PubMed/NCBI
17	Järvinen TA, Pelto-Huikko M, Holli K and Isola J: Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 156:29–35. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J and Shao ZM: ERβ exerts multiple stimulative effects on human breast carcinoma cells. Oncogene. 23:5799–5806. 2004. View Article : Google Scholar : PubMed/NCBI
19	Knowlden JM, Gee JM, Robertson JF, Ellis IO and Nicholson RI: A possible divergent role for the oestrogen receptor α and β subtypes in clinical breast cancer. Int J Cancer. 89:209–212. 2000. View Article : Google Scholar : PubMed/NCBI
20	Jensen EV, Cheng G, Palmieri C, Saji S, Mäkelä S, Van Noorden S, Wahlström T, Warner M, Coombes RC and Gustafsson JA: Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA. 98:15197–15202. 2001. View Article : Google Scholar : PubMed/NCBI